Skip to main content

Pretherapeutic quantitative I-131 SPECT/CT for blood and tumour dosimetry in thyroid cancer patients with bone metastases: a pilot feasibility study

Journal
EJNMMI physics (Q1)
Published
20 August 2026
Study design
Unclassified
Evidence level
Level 5, Expert Opinion (CEBM 5)
Authors
Kyounghyoun Kwon, Dongkyu Oh, Ji Hye Kim, Jihyung Yoo, Yoo Sung Song, Wonmo Sung, et al.
PMID
43040069
DOI
10.1186/s40658-026-00927-8

Why clinicians should know about it

  • Picked for Medical Physics (top studies of the week, 22 November 2026): Quantitative SPECT/CT and Monte Carlo therapeutic dosimetry

Abstract

PURPOSE: I-131 radioactive iodine (RAI) is widely used in thyroid cancer patients with bone metastases (BM). While blood-based dosimetry has been standard for predicting marrow toxicity, tumour dosimetry remains an unmet need. We evaluated the feasibility of pretherapeutic quantitative I-131 SPECT/CT for patient-tailored dosimetry in poorly differentiated thyroid carcinoma (PDTC) patients with BM. METHODS: Five PDTC patients (18 BM lesions) underwent serial pre-therapeutic I-131 SPECT/CT (111 MBq, eight time points up to 120 h) with concurrent blood sampling. I-131 concentrations (MBq/g) were quantified using quantitative SPECT/CT technology and validated against gamma counting. Absorbed dose rates (Gy/h) for blood and tumours were estimated using Monte Carlo simulations (customized Geant4, cross-validated by TOPAS). Tumour absorbed doses were calculated via trapezoidal integration, and clinical outcomes were assessed after subsequent high-dose RAI therapy. RESULTS: Blood I-131 concentrations measured by SPECT/CT showed excellent agreement with gamma counting (p < 0.001). Blood absorbed doses per administered activity were comparable between SPECT/CT and conventional methods (p = 0.6250). Tumour I-131 concentration strongly correlated with absorbed dose rate, resulting in a regression equation [tumour absorbed dose rate (Gy/h) = 0.1256 × tumour RAI concentration (MBq/g) (R2 = 0.9918, p < 0.0001)]. Reducing imaging time points from 8 to 4 maintained the accuracy of absorbed dose estimation. Although exploratory, tumours with expected absorbed doses > 50 Gy after high-dose RAI showed no progression, whereas lower-dose lesions progressed more frequently (87.5%, p = 0.0161). CONCLUSION: In this pilot study, quantitative I-131 SPECT/CT demonstrated the reliability of pretherapeutic blood and tumour dosimetry in PDTC patients with BM. Although preliminary, these findings support its potential as a practical tool for personalized RAI therapy planning in thyroid cancer. Larger, prospective studies are warranted to validate clinical dose-response thresholds.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.